World's Best Scientists 2026 revealed!
Jan Cools

Jan Cools

D-Index & Metrics

Medicine

D-Index
79
Citations
25906
World Ranking
17460
National Ranking
220

Overview

Jan Cools is affiliated with KU Leuven in Belgium and has made significant contributions to the fields of Medicine and Biochemistry, Genetics, and Molecular Biology. Their research primarily focuses on molecular biology, public health, environmental and occupational health, hematology, immunology, and cancer research.

The scientist's research topics highlight a strong concentration in leukemia and lymphoma studies, including acute lymphoblastic leukemia research, acute myeloid leukemia research, lymphoma diagnosis and treatment, CAR-T cell therapy research, chronic myeloid leukemia treatments, epigenetics and DNA methylation, as well as cancer genomics and diagnostics.

Jan Cools has published extensively, with recent notable papers including:

  • PHGDH heterogeneity potentiates cancer cell dissemination and metastasis, 2022, Nature
  • A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling, 2023, Nature Cancer
  • Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia, 2020, Blood
  • Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping, 2022, American Journal of Hematology
  • Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma, 2021, Blood

The scientist frequently publishes in journals such as Blood and HemaSphere, with ten publications each, as well as in bioRxiv (Cold Spring Harbor Laboratory), Haematologica, and Nature. This reflects a broad engagement with hematology and molecular biology-oriented scientific venues.

Collaboration is also a significant aspect of their research activity. Frequent co-authors include Sofie Demeyer, Olga Gielen, Heidi Segers, Nicole Mentens, and Kris Jacobs, indicating a network focused on related biomedical and hematological research.

Best Publications

  • Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

    Ross L. Levine;Ross L. Levine;Martha Wadleigh;Jan Cools;Benjamin L. Ebert;Benjamin L. Ebert

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

    Jinghui Zhang;Li Ding;Linda Holmfeldt;Gang Wu

  • Fusion of TEL, the ETS-Variant Gene 6 (ETV6), to the Receptor-Associated Kinase JAK2 as a Result of t(9; 12) in a Lymphoid and t(9; 15; 12) in a Myeloid Leukemia

    Pieter Peeters;Sophie D. Raynaud;Jan Cools;Iwona Wlodarska

  • Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

    Maria Debiec-Rychter;Jan Cools;Herlinde Dumez;Raf Sciot

  • Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.

    Hilde Brems;Magdalena Chmara;Magdalena Chmara;Mourad Sahbatou;Ellen Denayer

  • Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.

    Amy D. Klion;Amy D. Klion;Pierre Noel;Pierre Noel;Cem Akin;Cem Akin;Melissa A. Law;Melissa A. Law

  • Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia

    C Graux;Jan Cools;C Melotte;H Quentmeier

  • Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia

    Kim De Keersmaecker;Zeynep Kalender Atak;Ning Li;Carmen Vicente

  • CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

    Animesh Pardanani;Animesh Pardanani;Animesh Pardanani;Rhett P. Ketterling;Rhett P. Ketterling;Rhett P. Ketterling;Stephanie R. Brockman;Stephanie R. Brockman;Stephanie R. Brockman;Heather C. Flynn;Heather C. Flynn;Heather C. Flynn

  • The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

    Jason Gotlib;Jason Gotlib;Jason Gotlib;Jan Cools;Jan Cools;Jan Cools;James M. Malone;James M. Malone;James M. Malone;Stanley L. Schrier;Stanley L. Schrier;Stanley L. Schrier

  • Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

    Hans Prenen;Jan Cools;Nicole Mentens;Cedric Folens

  • Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast.

    Carlos Graux;Jan Cools;Lucienne Michaux;Peter Vandenberghe

  • The genetics and molecular biology of T-ALL

    Tiziana Girardi;Carmen Vicente;Carmen Vicente;Jan Cools;Jan Cools;Kim De Keersmaecker

  • Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.

    Jan Cools;Iwona Wlodarska;Riet Somers;Nicole Mentens

  • Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification

    Sara De Brouwer;Katleen De Preter;Candy Kumps;Piotr Zabrocki

  • Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia

    Idoya Lahortiga;Kim De Keersmaecker;Kim De Keersmaecker;Pieter Van Vlierberghe;Carlos Graux;Carlos Graux;Carlos Graux

  • PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

    Jan Cools;Elizabeth H Stover;Christina L Boulton;Christina L Boulton;Jason Gotlib

  • The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia

    Pieter Van Vlierberghe;Martine van Grotel;Joëlle Tchinda;Charles Lee

  • Duplication of the MYB oncogene in T-cell acute lymphoblastic leukemia

    Idoya Lahortiga;Kim De Keersmaecker;Pieter Van Vlierberghe;C. Graux

Frequent Co-Authors

Peter Marynen
Peter Marynen KU Leuven
Stein Aerts
Stein Aerts KU Leuven
Franki Speleman
Franki Speleman Ghent University
D. Gary Gilliland
D. Gary Gilliland Fred Hutchinson Cancer Research Center
Tom Taghon
Tom Taghon Ghent University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t have to follow a traditional path. Many students begin by pursuing alternative healthcare degrees or certifications online. For example, becoming a nurse can be more attainable by applying to the easiest bsn program to get into, which offers flexible admissions and a smoother route for those starting their healthcare journey.

Other in-demand options include medical billing and coding, which provide stable career opportunities with less time commitment than a full medical degree. There are online medical billing and coding schools that accept fafsa, making quality training both accessible and affordable to more students.

Additionally, if you want to work in nursing but wish to avoid certain testing barriers, you can consider nursing programs without teas exams, which streamline the entry process for prospective nurses.

For those interested in the administrative side of healthcare, accelerated healthcare programs are also available online, allowing you to complete your studies in less time and enter the workforce quickly.

Best Scientists Citing Jan Cools

Trending Scientists